| A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT06686615) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2025-02-12 |
| A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) (NCT05993234) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-12-05 |
| DESTINY Breast Respond HER2-(Ultra)Low Europe (NCT05945732) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-10-24 |
| Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (NCT05798390) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-09-01 |
| SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (NCT05546398) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2022-04-22 |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT04579367) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2021-01-15 |
| Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (NCT04271280) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2020-03-17 |
| Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (NCT02942576) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2017-03-21 |
| Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (NCT02866175) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2017-02-24 |
| Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (NCT02943993) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2016-04-06 |
| The Confirmatory Olmesartan Plaque Regression Study (NCT01132768) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2010-05-01 |
| Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (NCT01101009) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2010-04-01 |
| Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (NCT00891267) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2008-10-01 |
| Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (NCT00676845) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2008-08-01 |
| Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (NCT00679484) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2008-06-01 |
| Isolated Systolic Hypertension in the Elderly and Very Elderly (NCT00751829) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2003-07-01 |
| Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly (NCT00751751) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2003-06-01 |